EyeGate Pharmaceuticals

EyeGate Pharma | Advanced therapeutics and drug delivery mechanisms for ophthalmic care.

Launch date

1998

Market cap

Enterprise valuation

Waltham Massachusetts (HQ)

Date	Investors	Amount	Round
Feb 2004	Innoven Partners	N/A	Series A
Jan 2007	Nexus Medical Partners	$2.0m	Series B
Mar 2008	Medicis Capital	$15.0m	Series C
Mar 2009	N/A	$490k	Debt
Jan 2010	Ventech Natixis Private Equity Generis Capital Partners Innoven Partners Medicis Capital	$23.0k	Series D
Jan 2011	N/A	$5.9m	Series D
Aug 2015	N/A	N/A	IPO
Jul 2016	N/A	$3.8m	Post IPO Debt
Dec 2019	N/A	$1.9m	Post IPO Equity
Jan 2021	N/A	$8.0m	Post IPO Equity
Aug 2021	N/A	$10.8m	Post IPO Equity
Jul 2022*	N/A	$6.0m	Post IPO Equity
Nov 2022*	N/A	$3.1m	Post IPO Equity
Jan 2024*	Nantahala Capital Management Stonepine Capital Management ADAR1 Partners Rosalind Capital Partners Velan Capital	$45.0m	Post IPO Equity
Total Funding		AUD35.4m

Tech stackLearn more about the technologies and tools that this company uses.

ACQUISITION by EyeGate Pharmaceuticals Dec 2020

ACQUISITION by EyeGate Pharmaceuticals Mar 2016

Recent News about EyeGate Pharmaceuticals